

Programme

29th October

15.45-16.15. Registration and congress documentation

16.15. Opening

Mariano Barbacid (Fundación Areces), Jesús San Miguel, Ignacio Melero, Jose Luis Pérez Gracia, Pedro Berraondo

16.30 – 17.00. Keynote Lecture

Chair: Pedro Berraondo. CIMA. Ignacio Melero. CIMA y CUN

Future of cancer immunotherapy: Enhancement or normalization?

Lieping Chen. Yale. USA

17.00 – 18.00. Break

18.00 – 20.40. Exploiting tumor antigenicity

Chair: Juanjo Lasarte. CIMA. Pablo Sarobe. CIMA

18.00. The Yin and Yang of Cancer Immunotherapy Combinations

Daniel Chen. Roche Genentech. USA

18.40. Targeting Ideal Antigens for Cancer Immunotherapy

Özlem Türeci. BioNTech. Germany

19.20. Cancer immunotherapy beyond PD-1: novel pathways and combinations

Andrea van Elsas. ADURO. Netherlands

20.00. Radiotherapy and immunotherapy shoulder to shoulder into the fray

Silvia Formenti. Cornell. USA

30th October

09.00 – 10.00. Title: Immunotherapy development: industrial view and pipelines (1)

Chair: Jose Luis Pérez Gracia. CUN, Felipe Calvo. Hospital Gregorio Marañón. Madrid

09.00. Novel Drug Combinations for Cancer Immunotherapy

Nils Lonberg. BMS. USA

09.20. Medimmune cancer immunotherapy approach

Bahija Jallal. Medimmune. USA

09.40. MSD cancer immunotherapy approach

David Kaufman. MSD. USA

10.00 – 10.40. Round table discussion

10.40 – 11.00. Coffee break

11.00 – 12.20. Immunotherapy development: industrial view and pipelines (2)

Chair: Luis Paz-Ares. Hospital Universitario Doce de Octubre. Madrid. Spain, Luis Montuenga. CIMA

11.00. Advances in CAR T cell therapy: CD19 Therapy and Beyond

Jennifer Brogdon. Novartis. USA

11.20. Building a Next-Generation Immuno-Oncology Pipeline in a Competitive Space: Perspectives from a “New Kid on the Block”

Lazslo Radvanyi. Merck Serono. USA

11.40. A therapeutic strategy to target cold tumors

Eric Borges. Boehringer Ingelheim. Germany

12.00. The Lilly Immunooncology pipeline: enabling rational combinations

Michael Kalos. Lilly. USA

12.20 – 12.40. Round table discussion

12.45- 14.00- Lunch break

14.00-14.30. Keynote lecture

Chair: Ignacio Melero. CIMA y CUN, Ruth Vera. Hospital de Navarra

Clinical development of lung cancer immunotherapy

Luis Paz-Ares. Hospital Universitario Doce de Octubre. Madrid. Spain

14.30 – 16.30. Immunotherapy based on evidence

Chair: Ruben Pío. CIMA, María Rodríguez. CIMA y CUN

14.30. Targeting immune modulation at the tumour site

Sergio Quezada. UCL. UK

15.10. Anti-cancer immune therapy of melanoma

Mario Sznol. Yale. USA

15.50. Exploiting radiotherapy in immunotherapy combinations

Timothy Illidge. The University of Manchester. UK

16.30 – 16.50. Coffee break

16.50 – 18.50. Immunotherapy biomarkers, working in the tissue

Chair: Dolores Lozano. CUN, Miguel Idoate. CUN

16.50. Understanding the tumor immune composition using multiplexed quantitative approaches

Kurt Schalper. Yale. USA

17.30. Diagnostics in the era of Cancer Immunotherapy

Priti Hegde. Roche Genentech. USA

18.10. Role of Immunotherapy in Hodgkin and non-Hodgkin Lymphomas

Scott J. Rodig. Brigham and Women's Hospital. USA

31st October

09.00 – 11.00. TNFR costimulation in action

Chair: David Escors. Navarrabiomed. Spain, Fernando Pastor. CIMA

09.00. CD40 stimulation: the rules of a complex game

Ann White. UCB Celltech. UK

09.40. Moving forward CD137-based immunotherapies

Ignacio Melero. CIMA y CUN

10.20 GITR and 4-1BB in chronic viral infection: implications for cancer therapy

Tania Watts. University of Toronto. Canada

11.00 – 11.30. Coffee break

11.30 – 14.10. Genetics and genetic intervention for better immunotherapies

Chair: Cristian Smerdou. CIMA, Rubén Hernández Alcoceba. CIMA

11.30. Identification of immunoreactive microsatellite stable (MSS)

colorectal cancer for potential immune interventions

Nicolas J LLoza. Johns Hopkins. USA

12.10. Deconstructing the T cell Receptor signaling nanomachine

Balbino Alarcón. CBM. Spain

12.50. Viruses and IFN α / β in immunotherapy

Pedro Berraondo. CIMA

13.30. Viral gene therapies

Ramón Alemany. VCN. Spain

14.10 – 15.30. Lunch break

15.30 – 17.40. Exploiting new tools to improve immunotherapy

Chair: Susana Inogés. CUN, Ignacio Gil Bazo. CUN

15.30. Complement in cancer immunotherapy

Rubén Pío. CIMA. Spain

16.10. Patient-derived tumor models for immunotherapy development

Miguel Sanmamed. Yale. USA

17.00. Identifying T cells specific against cancer

Alena Gros. Vall d'Hebron. Spain

Event supported by:



With the collaboration:



**International Symposium:
"Trailblazing in cancer Immunotherapy"**

OCTOBER, 29th-31st



Fundación Ramón Areces

VENUE

Modern art museum. University of Navarra.
Pamplona, Spain

SYMPOSIUM COORDINATORS

Dr. Ignacio Melero
Dr. Pedro Berraondo
Dr. Jose Luis Pérez Gracia

ORGANIZERS

Fundación para la Investigación Médica Aplicada
Clínica Universidad de Navarra

CONTACT

simposioareces@unav.es

REGISTRATIONS

<http://simposioareces2017.viajesarga.com>